A real-world study found rates of toxicity-related T-DXd discontinuation in HER2-low metastatic breast cancer similar to those observed in DESTINY-Breast04. A real-world cohort of patients with ...

A significant portion of patients with locally advanced breast cancer receiving ultra-hypofractionation radiotherapy responded to treatment. Ultra-hypofractionated radiotherapy showed signs of ...

Antonio Ocejo, MD, discusses supportive care implications from new data comparing ipilimumab/nivolumab in older vs younger ...

Teclistamab plus daratumumab hyaluronidase-fihj has been approved for patients with relapsed/refractory multiple myeloma as part of the CNPV program. The FDA has approved teclistamab (Tecvayli) ...

While the combination of pembrolizumab with standard-of-care (SOC) radiation, and androgen deprivation therapy with or without olaparib (Lynparza) was found generally feasible in high-risk localized ...

The most frequent treatment-emergent AEs for belzutifan/lenvatinib were anemia (69.2%), hypertension (58.9%), and diarrhea (52.7%); the cabozantinib arm saw frequent diarrhea (70.1%), hypertension (56 ...

Patients with resected renal cell carcinoma (RCC) receiving adjuvant durvalumab (Imfinzi) plus tremelimumab-actl (Imjudo) experienced early reductions in patient-reported quality of life (QoL), ...

While every patient with cancer will have psychosocial needs, understanding when to assess those needs and what professionals to connect a patient with are key to supporting patie ...

Zongertinib has been granted accelerated approval in NSCLC harboring HER2 TKD mutations as part of the Commissioner’s ...

Final phase 3 EORTC 1333/PEACE-3 data show enzalutamide plus radium-223 extends OS and radiographic progression-free survival in mCRPC with bone metastases. Final data from the phase 3 EORTC ...

The Oncology Nursing Society (ONS) is developing a skin of color toxicity photo repository with funding from a grant from La Roche-Posay to support oncology nurses in recognizing ...

Treatment with systemic intravenous olvimulogene nanivacirepvec (Olvi-Vec) led to promising preliminary results in patients with progressive non–small cell lung cancer (NSCLC) and progressive SCLC ...